Drug Approval | December 11, 2025
Roche secures European nod for Gazyva/Gazyvaro in Lupus Nephritis patients
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
76 of 180 long COVID-associated genes also linked to ME
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Subscribe To Our Newsletter & Stay Updated
